Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-24T13:50:46.374Z Has data issue: false hasContentIssue false
  • English
  • Français

Brain glutathione levels and age at onset of illness in chronic schizophrenia

Published online by Cambridge University Press:  27 August 2019

Yvonne S. Yang Open the ORCID record for Yvonne S. Yang [Opens in a new window] ,
Richard J. Maddock ,
Junghee Lee ,
Huailin Zhang ,
Gerhard Hellemann ,
Katherine L. Narr ,
Stephen R. Marder  and
Michael F. Green
Yvonne S. Yang*
Affiliation:
VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA
Richard J. Maddock
Affiliation:
Department of Psychiatry and Biobehavioral Sciences, University of California, Davis, CA, USA
Junghee Lee
Affiliation:
VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA
Huailin Zhang
Affiliation:
David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Gerhard Hellemann
Affiliation:
Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA
Katherine L. Narr
Affiliation:
Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA Department of Neurology, University of California, Los Angeles, CA, USA
Stephen R. Marder
Affiliation:
VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA
Michael F. Green
Affiliation:
VISN22 Mental Illness Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA
*
Author for correspondence: Yvonne S. Yang, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Oxidative stress is implicated in the aetiology of schizophrenia, and the antioxidant defence system (AODS) may be protective in this illness. We examined the major antioxidant glutathione (GSH) in prefrontal brain and its correlates with clinical and demographic variables in schizophrenia.

Methods:

GSH levels were measured in the dorsolateral prefrontal region of 28 patients with chronic schizophrenia using a magnetic resonance spectroscopy sequence specifically adapted for GSH. We examined correlations of GSH levels with age, age at onset of illness, duration of illness, and clinical symptoms.

Results:

We found a negative correlation between GSH levels and age at onset (r = −0.46, p = 0.015), and a trend-level positive relationship between GSH and duration of illness (r = 0.34, p = 0.076).

Conclusion:

Our findings are consistent with a possible compensatory upregulation of the AODS with longer duration of illness and suggest that the AODS may play a role in schizophrenia.

Keywords

schizophreniaoxidative stressglutathioneage of onset
Type
Short Communication
Information
Acta Neuropsychiatrica , Volume 31 , Issue 6 , December 2019 , pp. 343 - 347
Copyright
© Scandinavian College of Neuropsychopharmacology 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

An, L, Zhang, Y, Thomasson, DM, Latour, LL, Baker, EH, Shen, J and Warach, S (2009) Measurement of glutathione in normal volunteers and stroke patients at 3T using J-difference spectroscopy with minimized subtraction errors. Journal of Magnetic Resonance Imaging: JMRI 30(2), 263–270.Google ScholarPubMed
Barron, H, Hafizi, S, Andreazza, A and Mizrahi, R (2017) Neuroinflammation and oxidative stress in psychosis and psychosis risk. International Journal of Molecular Sciences 18(3), 651–663.Google ScholarPubMed
Berk, M, Copolov, D, Dean, O, Lu, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M, Judd, F, Katz, F, Katz, P, Ording-Jespersen, S, Little, J, Conus, P, Cuenod, M, Do, KQ and Bush, AI (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 64(5), 361–368.CrossRefGoogle ScholarPubMed
Brandt, AS, Unschuld, PG, Pradhan, S, Lim, IAL, Churchill, G, Harris, AD, Hua, J, Barker, PB, Ross, CA, van Zijl, PC, Edden, RA and Margolis, RL (2016) Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a 1H MRS Study at 7Tesla. Schizophrenia Research 172(1–3), 101–105.CrossRefGoogle Scholar
Da Silva, T, Hafizi, S, Andreazza, AC, Kiang, M, Bagby, RM, Navas, E, Laksono, I, Truong, P, Gerritsen, C, Prce, I, Sailasuta, N and Mizrahi, R (2017) Glutathione, the major redox regulator, in the prefrontal cortex of individuals at clinical high risk for psychosis. International Journal of Neuropsychopharmacology 21(4), 311–318.CrossRefGoogle Scholar
Do, KQ, Trabesinger, AH, Kirsten-Krüger, M, Lauer, CJ, Dydak, U, Hell, D, Holsboer, F, Boesiger, P and Cuénod, M (2001) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience 12(10), 3721–3728.CrossRefGoogle Scholar
Emir, UE, Deelchand, D, Henry, P-G and Terpstra, M (2011) Noninvasive quantification of T2 and concentrations of ascorbate and glutathione in the human brain from the same double-edited spectra. NMR in Biomedicine 24(3), 263–269.CrossRefGoogle ScholarPubMed
Ernst, T and Chang, L (1996) Elimination of artifacts in short echo time H MR spectroscopy of the frontal lobe. Magnetic Resonance in Medicine 36(3), 462–468.Google ScholarPubMed
Koga, M, Serritella, AV, Sawa, A and Sedlak, TW (2016) Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophrenia Research 176(1), 52–71.CrossRefGoogle ScholarPubMed
Kumar, J, Liddle, EB, Fernandes, CC, Palaniyappan, L, Hall, EL, Robson, SE, Simmonite, M, Fiesal, J, Katshu, MZ, Qureshi, A, Skelton, M, Christodoulou, NG, Brookes, MJ, Morris, PG and Liddle, PF (2018) Glutathione and glutamate in schizophrenia: a 7T MRS study. Molecular Psychiatry 38, 942–10. doi.org/10.1038/s41380-018-0104-7 Google Scholar
Lesh, TA, Maddock, RJ, Howell, A, Wang, H, Tanase, C, Ragland, JD, Niendam, TA and Carter, CS (2019) Extracellular free water and glutathione in first-episode psychosis – a multimodal investigation of an inflammatory model for psychosis. Molecular Psychiatry 45(3), 189. doi.org/10.1038/s41380-019-0428-y Google Scholar
Mandal, PK, Saharan, S, Tripathi, M and Murari, G (2015) Brain glutathione levels – a novel biomarker for mild cognitive impairment and Alzheimer’s disease. Biological Psychiatry 78(10), 702–710.Google ScholarPubMed
Marjańska, M, Emir, UE, Deelchand, DK and Terpstra, M (2013) Faster metabolite 1H transverse relaxation in the elder human brain. PLoS ONE 8(10), e77572–e77577.Google Scholar
Matsuzawa, D, Obata, T, Shirayama, Y, Nonaka, H, Kanazawa, Y, Yoshitome, E, Takanashi, J, Matsuda, T, Shimizu, E, Ikehira, H, Iyo, M and Hashimoto, K (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 3(4), e1944–1946.CrossRefGoogle ScholarPubMed
Mescher, M, Merkle, H, Kirsch, J, Garwood, M and Gruetter, R (1998) Simultaneous in vivo spectral editing and water suppression. NMR in Biomedicine 11(6), 266–272.Google ScholarPubMed
Minati, L, Aquino, D, Bruzzone, MG and Erbetta, A (2010) Quantitation of normal metabolite concentrations in six brain regions by in-vivo H-MR spectroscopy. Journal of Medical Physics/Association of Medical Physicists of India 35(3), 154–163.Google Scholar
Mischley, LK, Standish, LJ, Weiss, NS, Padowski, JM, Kavanagh, TJ, White, CC and Rosenfeld, ME (2016) Glutathione as a biomarker in Parkinson’s disease: associations with aging and disease severity. Oxidative Medicine and Cellular Longevity 2016(3), 9409363–9409366.Google ScholarPubMed
Mlynárik, V, Gruber, S and Moser, E (2001) Proton T (1) and T (2) relaxation times of human brain metabolites at 3 Tesla. NMR in Biomedicine 14(5), 325–331.CrossRefGoogle Scholar
Ongür, D, Prescot, AP, Jensen, JE, Cohen, BM and Renshaw, PF (2009) Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Research: Neuroimaging 172(1), 44–48.CrossRefGoogle ScholarPubMed
Pasternak, O, Westin, C-F, Bouix, S, Seidman, LJ, Goldstein, JM, Woo, T-UW, Petryshen, TL, Mesholam-Gately, RI, McCarley, RW, Kikinis, R, Shenton, ME and Kubicki, M (2012) Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 32(48), 17365–17372.Google ScholarPubMed
Rae, CD and Williams, SR (2017) Glutathione in the human brain: review of its roles and measurement by magnetic resonance spectroscopy. Analytical Biochemistry 529, 127–143.CrossRefGoogle ScholarPubMed
Sanaei Nezhad, F, Anton, A, Parkes, LM, Deakin, B and Williams, SR (2017) Quantification of glutathione in the human brain by MR spectroscopy at 3 Tesla: comparison of PRESS and MEGA-PRESS. Magnetic Resonance in Medicine 78(4), 1257–1266.CrossRefGoogle ScholarPubMed
Steullet, P, Cabungcal, JH, Monin, A, Dwir, D, O’Donnell, P, Cuenod, M and Do, KQ (2016) Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? Schizophrenia Research 176(1), 41–51.Google Scholar
Terpstra, M, Henry, P-G and Gruetter, R (2003) Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magnetic Resonance in Medicine 50(1), 19–23.CrossRefGoogle ScholarPubMed
Träber, F, Block, W, Lamerichs, R, Gieseke, J and Schild, HH (2004) 1H metabolite relaxation times at 3.0 tesla: measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. Journal of Magnetic Resonance Imaging: JMRI 19(5), 537–545.Google ScholarPubMed
Tsai, M-C, Liou, C-W, Lin, T-K, Lin, I-M and Huang, T-L (2013) Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs. Psychiatry Research 209(3), 284–290.Google ScholarPubMed
Wood, SJ, Berger, GE, Wellard, RM, Proffitt, T-M, McConchie, M, Berk, M, McGorry, PD and Pantelis, C (2009) Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiology of Disease 33(3), 354–357.Google ScholarPubMed
Xin, L, Mekle, R, Fournier, M, Baumann, PS, Ferrari, C, Alameda, L, Jenni, R, Lu, H, Schaller, B, Cuenod, M, Conus, P, Gruetter, R and Do, KQ (2016) Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis. Schizophrenia Bulletin 42(5), 1185–1196.CrossRefGoogle ScholarPubMed